Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer

Prognostic factors for long‐term survival following complete resection by lobectomy in stage I non‐small cell lung cancer

“…We show that both classic prognostic markers such as DLCO, FEV1, and male gender, but also NLR as a more recent surrogate parameter for systemic inflammation, have a statistically significant, independent impact on long‐term OS. Unlike most other studies, we demonstrate this in a homogeneous, single‐center collective strictly focusing on stage I patients who had undergone complete resection by lobectomy 6–11 . The common practice to examine stages I to III together results in patient cohorts where pT1 pN0 patients are mixed with patients who have a pT4 tumor and/or a pN2 or pN3 stage.…”

“…Unlike most other studies, we demonstrate this in a homogeneous, single‐center collective strictly focusing on stage I patients who had undergone complete resection by lobectomy. 6 , 7 , 8 , 9 , 10 , 11 The common practice to examine stages I to III together results in patient cohorts where pT1 pN0 patients are mixed with patients who have a pT4 tumor and/or a pN2 or pN3 stage. In our view, these are patient populations that may well differ in tumor biology and tumor‐associated inflammation.…”

“…stage IV) or multimodal treatment or targeted immunotherapy. 6 , 7 , 8 , 9 , 10 , 11 , 12 Furthermore, many studies focus on biomarkers but neglect other clinically relevant variables, such as FEV1 and DLCO which are known to have significant prognostic relevance for patients with lung cancer. 13 , 14 This is also mostly true for the few studies that explicitly address stage I NSCLC.…”

“…However, most studies on this topic have inhomogeneous patient populations (e.g., stage I–III) and include patients with advanced tumor stage (e.g. stage IV) or multimodal treatment or targeted immunotherapy 6–12 . Furthermore, many studies focus on biomarkers but neglect other clinically relevant variables, such as FEV1 and DLCO which are known to have significant prognostic relevance for patients with lung cancer 13,14 .…”

Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’

“…published by ESMO Open. 1 In the study, the authors evaluated the prognostic significance of various biomarkers of the systemic inflammatory response, for example, neutrophil count, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, prognostic nutritional index, and serum albumin level, in patients receiving first-line pembrolizumab for advanced non-small-cell lung cancer (NSCLC). In addition, they created the Scottish Inflammatory Prognostic Score based on two factors, albumin and neutrophil count, which were independent prognostic factors for progression-free survival and overall survival on multivariate analysis in their study.…”